Oncospherix Inc.
Atlanta, GA
- UEI
- HKZYM5YC7KR7
- CAGE
- 88S68
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 7935 Fawndale Way, Atlanta, GA 30350, USA
- Website
- oncospherix.com
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Arylsulfonamides for the treatment of primary and metastatic uveal melanoma | National Cancer Institute (NIH) | $3,074,999 | |
| Arylsulfonamides for the treatment of primary and metastatic uveal melanoma | National Cancer Institute (NIH) | $399,774 |
Quick answers
Is Oncospherix Inc. registered in SAM.gov?
Yes. Oncospherix Inc.'s SAM.gov registration is active through May 31, 2027.
What is Oncospherix Inc.'s most recent federal award?
Oncospherix Inc.'s most recent federal grant award is Arylsulfonamides for the treatment of primary and metastatic uveal melanoma (R44CA254756), from National Cancer Institute (NIH), on September 17, 2020.
On GovTribe
See Oncospherix Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors